Noninvasive Diagnostic NephroSant has developed a reliable, inexpensive, noninvasive assay to monitor kidney injury in transplant patients, presenting a clear value proposition for hospitals and transplant centers seeking early detection of graft injury and reduced rejection costs.

Clinical Commercialization Recent leadership addition of a chief commercialization officer and the imminent LDT launch for Qsant indicate a focused push toward frontline commercialization, offering sales targets access points at transplant centers, pathology labs, and reference labs.

Early Revenue Opportunity With a Series A completed and a current revenue range of one to ten million, there is an opportunity to upsell to tiered adoption at multiple transplant programs and sites participating in LDT deployments.

Tech & Data Enablement The tech stack includes cloud and analytics tools (AWS, Spark, Tableau, Power BI) enabling scalable data integration and reporting, which can resonate with healthcare systems pursuing data-driven outcomes and outcomes-based contracts.

Strategic Partnerships Operating out of UCSF and targeting kidney transplant networks, NephroSant can pursue partnerships with major transplant centers, pathology groups, and payer-aligned institutions to accelerate adoption and reimbursement pathways.